M. A. Jewett

Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment.

T. H. van der Kwast, S. Culine, A. Broeks, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: the Princess Margaret Hospital experience.

I. Tannock, M. Gospodarowicz, M. Jewett, 1989, The Journal of urology.

The International Testicular Cancer Linkage Consortium: a clinicopathologic descriptive analysis of 461 familial malignant testicular germ cell tumor kindred.

D. Bishop, M. Stratton, K. Heimdal, 2010, Urologic oncology.

Surveillance for stage I testicular seminoma. Is it a good option?

P. Warde, M. Jewett, M. A. Jewett, 1998, The Urologic clinics of North America.

Bladder cancer: long-term follow-up results of patients treated with radical radiation.

P. Warde, M. Gospodarowicz, B. Cummings, 1991, Clinical oncology (Royal College of Radiologists (Great Britain)).

Radical radiotherapy for muscle invasive transitional cell carcinoma of the bladder: failure analysis.

J. Herman, M. Gospodarowicz, G. Thomas, 1989, The Journal of urology.

Partial orchiectomy: The Princess Margaret cancer centre experience.

R. Hamilton, L. Anson-Cartwright, G. Nason, 2020, Urologic oncology.

Management of stage I non-seminomatous testicular cancer: a systematic review and meta-analysis.

J. Chin, S. Hotte, M. Jewett, 2010, Clinical oncology (Royal College of Radiologists (Great Britain)).